Mitomycin C (Teva) Inj 20 mg vial: Supply issue

Supply issue Active

There is a supply issue affecting Teva mitomycin C (pharmacode: 2601761).

Affected product

Mitomycin C

PCT only- Specialist

  • Presentation: Inj 20 mg vial
  • Brand: Teva
  • Pharmacode: 2601761
  • Subsidy: $1250.00
  • Measure / Qty: per 1

Alternative listed 

Teva has sourced a supply of Omegapharma mitomycin C, which will be supplied under Section 29 until the Teva brand is back in stock. Teva has supplied the Omegapharma brand before, but registration has now lapsed.

This stock will have Australian packaging.

  • Presentation: Inj 20 mg vial
  • Brand: Omegapharm
  • Unapproved medicine supplied under Section 29.
  • Pharmacode: 2580160 
  • Subsidy: $1250.00
  • Measure / Qty: per 1

Information about Omegapharm mitomycin C on the Australian Medicinewise website(external link)

Expected resupply August 2024

Teva (the supplier) expect Teva brand mitomycin C to be resupplied in August 2024. 

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)